M6229

DRUG2 trials

Sponsors

A.P.J. Vlaar, Matisse Pharmaceuticals

Conditions

Critical IllnessHealthy SubjectsSepsisSeptic Shock

Phase 1

Intravenously Administered M6229 in Critically Ill Sepsis Patients

CompletedNCT05208112

A.P.J. VlaarCritical Illness, Sepsis, Septic Shock

Start: 2022-04-05End: 2023-09-28Updated: 2025-02-11

A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229

CompletedNCT07285603

Matisse PharmaceuticalsHealthy Subjects

Start: 2024-11-21End: 2025-06-18Updated: 2025-12-16